Hypofractionated radiation therapy (HFRT) versus conventional fractionated radiation therapy (CRT) for newly diagnosed glioblastoma patients. A propensity score matched analysis. Issue 1 (April 2018)
- Record Type:
- Journal Article
- Title:
- Hypofractionated radiation therapy (HFRT) versus conventional fractionated radiation therapy (CRT) for newly diagnosed glioblastoma patients. A propensity score matched analysis. Issue 1 (April 2018)
- Main Title:
- Hypofractionated radiation therapy (HFRT) versus conventional fractionated radiation therapy (CRT) for newly diagnosed glioblastoma patients. A propensity score matched analysis
- Authors:
- Navarria, Pierina
Pessina, Federico
Franzese, Ciro
Tomatis, Stefano
Perrino, Matteo
Cozzi, Luca
Simonelli, Matteo
Bello, Lorenzo
Clerici, Elena
Riva, Marco
Santoro, Armando
Scorsetti, Marta - Abstract:
- Abstract: Background: The current treatment for newly diagnosed glioblastoma consists of surgery followed by conventional radiotherapy (CRT) with concomitant and adjuvant chemotherapy. Hypofractionated radiation therapy (HFRT) has been investigated and it resulted feasible and safe. The aim of this study was to evaluate whether HFRT can be comparable to CRT. Materials and methods: The analysis included newly diagnosed glioblastoma patients treated with CRT 60 Gy/30 fractions or HFRT 60 Gy/15 fractions. A propensity score matching analysis (PSM) was performed using a logistic regression that considered age, KPS, extent of surgery, MGMT and IDH status. Results: A total of 267 patients were included; before PSM 169 were in CRT-group and 98 in HRFT-group. After 1:1 matching, 82 patients resulted in each group. The median OS time was 17.9 months for the CRT-group and 16.7 months for the HFRT-group; the 1, 2, 3-year OS rates were 75.6%, 32.7%, and 15.5% for the CRT-group, and 75.6%, 33.3%, and 18.9% for the HFRT-group ( p value = 0.8). No statistically significant differences were recorded between the two radiation therapy treatments performed. Conclusions: A short course of radiation therapy would seem comparable to CRT in terms of outcome and less burdensome for these poor prognosis patients.
- Is Part Of:
- Radiotherapy and oncology. Volume 127:Issue 1(2018)
- Journal:
- Radiotherapy and oncology
- Issue:
- Volume 127:Issue 1(2018)
- Issue Display:
- Volume 127, Issue 1 (2018)
- Year:
- 2018
- Volume:
- 127
- Issue:
- 1
- Issue Sort Value:
- 2018-0127-0001-0000
- Page Start:
- 108
- Page End:
- 113
- Publication Date:
- 2018-04
- Subjects:
- Glioblastoma -- Radiation therapy -- Propensity score matching
Oncology -- Periodicals
Radiotherapy -- Periodicals
Tumors -- Periodicals
Medical Oncology -- Periodicals
Neoplasms -- radiotherapy -- Periodicals
Radiotherapy -- Periodicals
Radiothérapie -- Périodiques
Cancérologie -- Périodiques
Tumeurs -- Périodiques
Electronic journals
616.9940642 - Journal URLs:
- http://www.sciencedirect.com/science/journal/01678140 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/01678140 ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/01678140 ↗
http://www.estro.org/ ↗
http://www.elsevier.com/journals ↗
http://www.journals.elsevier.com/radiotherapy-and-oncology/ ↗ - DOI:
- 10.1016/j.radonc.2017.12.006 ↗
- Languages:
- English
- ISSNs:
- 0167-8140
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 7240.790000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 6398.xml